Retifanlimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It can be used for the research of gastroesophageal adenocarcinoma (GEA). MW :145.64 KD.